Canine adenovirus vectors for the transfer of genes in targeted cells
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
May 29, 2003
app pub date -
Jun 7, 2002
filing date -
Dec 7, 1999
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
Recombinant Canine Adenovirus (CAV) vectors based on CAV-2 strain Toronto in which the CAV-2 E1 region has been deleted are described herein. Methods for the preparation of recombinant vectors include the use of transcomplementation cell lines which are specifically employed to reduce the likelihood of generating replication competent CAV-2 during propagation of the vectors. The resultant replication-defective, E1-deficient CAV preparations are highly desirable for the transfer of nucleic acid sequences in vitro and in vivo.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully